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ABSTRACT 
Osteoarthritis (OA) and the non-steroidal anti-inflammatory drugs (NSAIDs) used to relieve 
OA-associated pain have been linked independently to increased cardiovascular risk. We 
examined the risk of cardiovascular events associated with NSAID use in patients with OA. 
We employed linked nationwide administrative registers to examine NSAID use between 
1996 and 2015 by Danish patients with OA aged ≥18 years. Using adjusted Cox proportional 
hazard analyses, we calculated the risk of the composite outcome of cardiovascular death, 
non-fatal myocardial infarction and non-fatal ischaemic stroke/TIA, and of each outcome 
separately, up to 5 years after OA diagnosis. Of 533,502 patients included, 64.3% received 
NSAIDs and 38,226 (7.2%) experienced a cardiovascular event during follow-up. Compared 
with non-use, all NSAIDs were associated with increased risk of the composite outcome: 
hazard ratio (HR) for rofecoxib, 1.90 [95% Confidence Interval, 1.74–2.08]; celecoxib, 1.47 
[1.34-1.62]; diclofenac, 1.44 [1.36–1.54]; ibuprofen, 1.20 [1.15–1.25]; naproxen, 1.20 [1.04–
1.39]. Similar results were seen for each outcome separately. When celecoxib was used as 
reference, ibuprofen (HRs 0.81 [CI 0.74-0.90]) and naproxen (HRs 0.81 [0.68-0.97]) 
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exhibited a lower cardiovascular risk, even when low doses were compared. Low-dose 
naproxen and ibuprofen were associated with the lowest risks of the composite outcome 
compared to no NSAID use: HRs 1.12 [1.07-1.19] and 1.16 [0.92-1.42], respectively.  
In patients with OA, we found significant differences in cardiovascular risk among NSAIDs. 
Naproxen and ibuprofen appeared to be safer compared to celecoxib, also when we examined 
equivalent low doses. In terms of cardiovascular safety, naproxen and ibuprofen, at the lowest 
effective doses, may be the preferred first choices among patients with OA needing pain 
relief. 
 
Introduction 
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most frequently used 
medications 
1
. Nevertheless, since the publication of the VIGOR (Vioxx gastrointestinal 
outcomes research) study in 2000 
2
, concerns about the cardiovascular safety of NSAID have 
led to intense investigations of both selective and non-selective of NSAIDs’. 
3-5 
 
Osteoarthritis (OA) is the most common form of joint disease worldwide, 
6
 as well as a 
leading cause of chronic pain, disability and reduced quality of life resulting in a considerable 
burden to society 
7
. Still, NSAIDs are the cornerstone for effective pain management of 
patients with OA. 
8, 9
 OA and cardiovascular disease share diverse risk factors, such as 
ageing, obesity and physical inactivity. 
10
 Moreover, patients with OA have a high prevalence 
of cardiovascular risk factors such as hypertension, diabetes and hypercholesterolaemia; 
11
 
hence, they carry an elevated cardiovascular hazard
 
and are potentially more susceptible to 
cardiovascular adverse effects of NSAIDs
 
than the general population. 
12
  
NSAIDs provide their analgesic, antipyretic and anti-inflammatory effects through the 
inhibition of the enzyme cyclooxygenase, which catalyzes the rate-limiting step in the 
formation of prostanoids, prostaglandins and thromboxane A2. 
12
 The harmful cardiovascular 
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effect seems to be shared by all the drugs of this group. 
13
 Nonetheless, differences in 
pharmacokinetic and pharmacodynamic characteristics suggest drug-specific cardiovascular 
profiles. 
12
 
The FDA (Food and Drug Administration)-mandated PRECISION (Prospective Randomized 
Evaluation of Celecoxib Integrated Safety Vs Ibuprofen or Naproxen) trial, undertaken while 
celecoxib remained on the market, aimed to elucidate the comparative cardiovascular safety 
of celecoxib, ibuprofen and naproxen in patients with arthritis.
 14
  
The results of PRECISION are challenging to interpret owing to their numerous limitations. 
12, 15-17
 Conflicting opinions and debate remains about the cardiovascular profile and safety of 
celecoxib, ibuprofen and naproxen, especially at different dosages, in OA. This prompted us 
to examine an unselected cohort of patients with OA where we focused on risk of 
cardiovascular death, acute myocardial infarction (MI) and ischaemic stroke associated with 
the use of NSAIDs aiming to demonstrate whether differences existed between the individual 
drugs and their doses. 
 
Materials and Methods 
The study was conducted in accordance with the Basic & Clinical Pharmacology & 
Toxicology policy for experimental and clinical studies. 
18
 
 
Data sources  
In Denmark, every resident has a permanent and unique civil registration number that permits 
linkage between administrative registries. All hospital admissions have been recorded since 
1978 in the Danish National Patient Registry with one primary diagnosis and one or more 
secondary diagnoses, encoded according to the International Classification of Diseases (ICD), 
until 1994 the ICD-8 and from 1994 the ICD-10. The Danish National Prescription Registry 
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has since 1995 registered all prescriptions from pharmacies in Denmark and every drug is 
classified by the Anatomical Therapeutical Chemical (ATC) system. The Central Person 
Registry comprises information about vital and migration status. The National Causes of 
Death Register contains the cause of death registered using the ICD-10 classification system. 
 
Study population  
This nationwide cohort study includes all adult patients, aged ≥18 years with first contact 
with the Danish health care system (both hospitalization and ambulatory) for OA between 1 
January 1996 and 31 December 2015. 
We started follow-up 7 days after the discharge or out-patient contact (index date) until one 
of the following events (whichever came first): emigration, death, outcome of interest 
(cardiovascular death, non-fatal ischaemic stroke or MI), 5-year follow-up after index date or 
end of study period (31 December 2015). Patients were included in the analysis only if they 
were alive and had not yet experienced the outcomes of interest at the index date.    
 
Non-steroidal Anti-Inflammatory Drug Use  
We identified all claimed prescriptions for NSAIDs (ATC M01A, excluding M01AX05 
glucosamine) from the Danish National Prescription Registry after the index date. The most 
commonly used selective cyclooxygenase-(COX) 2 inhibitors, rofecoxib and celecoxib, and 
the most commonly used non-selective NSAIDs, ibuprofen, diclofenac and naproxen, were 
analysed separately. All other NSAIDs were analysed in a common group defined as ‘other 
NSAIDs’ (Supplementary table 1).  
 
 
 
A
cc
ep
te
d
 A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Dose and Duration of Treatment  
The national prescription registry does not include information on the prescribed daily dosage 
of medications. Accordingly, the daily dosage was determined at each new dispensed 
prescription by calculating average dose from up to three consecutive prescriptions prior to 
the actual one. For each prescription, the number of tablets dispensed was divided by the 
estimated daily dosage to calculate the treatment duration. This approach also allowed the 
dose to increase if subsequent prescriptions were filled before tablets were consumed. If 
tablets were still available for consumption based on the approximation of exposure at the 
time of a new prescription for the same NSAID, exposure was defined as an uninterrupted 
treatment episode. The approximation of drug exposure was based on continuous assessment 
of new prescriptions during exposure and not on future prescriptions; hence, exposure was 
not conditioned on future use. If only one prescription was registered for a patient, the daily 
dosage was estimated as the minimum recommended dosage. Discontinuation of the 
prescribed NSAID was defined as the point when patients had no more medication available. 
Patients were allowed to change the NSAID treatment regimen during the study period. 
Therefore, exposure to NSAIDs was included as a time-dependent variable in the models. 
The patients were permitted to be in only one drug exposure group at a time but could change 
groups. If a patient was exposed to more than one NSAID at the same time, we defined a 
sequence of use (rofecoxib, celecoxib, diclofenac, naproxen, other) to allow all explanatory 
variables in one model. The baseline NSAID treatment was defined as availability of tablets 
from seven days after hospital discharge or outpatient contact for OA to six months before. 
The method we employed has been described in detail in an online document and has been 
previously applied in other studies from our group. 
19-24
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High dose was defined as being above the upper limit of the recommended minimal dose for 
each drug 
25, 26
: ibuprofen >1200 mg; diclofenac >100 mg; naproxen >500 mg; rofecoxib >25 
mg; and celecoxib >200 mg. 
 
Comorbidity and concomitant medication 
The Ontario acute MI mortality prediction rule modified for the ICD-10 was used to identify 
comorbidity 
27
. Also, we identified discharge diagnoses up to 5 years before the index date.  
Concomitant use of β-blockers, angiotensin-converting enzyme inhibitors/angiotensin 2 
receptor blockers, statins, weak and strong opioids, and anti-diabetic drugs, the latter a proxy 
for prevalence of diabetes 
28
, was defined as claimed prescriptions within 180 days before 
index date. 
The exposure status to aspirin was continually updated during the follow-up period. We also 
identified joint replacement surgery (knee or hip alloplasty) and bone fractures during the 
follow-up period. In fact, patients with OA have an enhanced risk of undergoing alloplasty 
and fractures, which lead to augmented pain and so augmented use of painkillers. The codes 
used to identify comorbidity and medication are listed in Supplementary table 2. 
 
Outcome measures  
The primary outcome was a composite of cardiovascular death, non-fatal MI and non-fatal 
ischaemic stroke/transient ischemic attack. The three endpoints were also analysed 
separately. The diagnosis of MI in the Danish registries has previously been validated with a 
positive predictive value of 92 to 100% 
29
. Stroke was defined as cerebral infarction, 
unspecified stroke and transient ischaemic attack: this diagnosis has also been formerly 
validated with a positive predictive value of 97% 
30, 31
. The outcome cardiovascular death was 
defined as a combination of coronary death or death caused by thromboembolic events 
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(ischaemic stroke, transient ischaemic attack or arterial embolism) as done previously 
32
. 
Details on ICD codes used to classify the outcomes are listed in the Supplementary material 
(Supplementary table 2). 
 
Statistical Analysis  
We calculated crude incidence rates as number of events per 100 person years for the 
composite outcome of cardiovascular death, non-fatal MI and non-fatal ischaemic stroke 
according to NSAID-treatment. We estimated the effects of the different NSAIDs on the 
outcomes using adjusted Cox regression models in terms of hazard ratios (HRs) and 95% 
confidence intervals. Exposure to NSAIDs was included as a time-dependent variable in the 
models, ensuring that patients were only considered at risk when exposed to the respective 
drug. Each patient could have multiple independent treatment courses with the same drug but 
also with different drugs. Hence, current NSAID use was specifically compared with non-
current NSAID use in our main analyses. Similarly, in additional analyses, we used ibuprofen 
and celecoxib, overall and at low dose, as reference. Finally, we performed a series of 
additional subanalyses in which 1) we stratified by the localization of OA (knee, hip or 
spine), we included only individuals 2) with and without previous cardiovascular disease i.e. 
patients with and without MI, ischaemic heart disease, stroke or PAD, respectively, 3) new 
users of NSAIDs (defined as not exposed to NSAIDs during the six months before the index 
date) and 4) who underwent joint replacement surgery during follow-up.  
All models were adjusted for age, sex, concomitant medication and comorbidity as listed in 
Table 1. Bone fractures and aspirin use were included as a time-dependent variable.  
We also determined how the use of these drugs changed during the study period by 
calculating the number of patients who were in treatment with the various NSAIDs as 
percentage of the total included population.  
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Lastly, we performed Schneeweiss analyses 
33
 to assess how strong an unmeasured 
confounder, unbalanced distributed between the two compared groups, should be to fully 
explain the observed findings. 
We used Stata statistical package, version 14 (Stata-Corp LP) for the Cox proportional 
hazards analysis with time-dependent variables and incidence rates. The rest of the statistical 
analyses and data management were performed using the SAS statistical Software package, 
version 9.2 (SAS Institute, NC, USA). 
 
Ethics  
The Danish Data Protection Agency approved the study (No. 2007–58-015/ GEH-2014-018 
I-Suite number: 02736). Cohort studies based on data from administrative registers do not 
require ethical approval in Denmark. 
 
Results 
Characteristics 
The study population comprised 533,502 people with a median age of 62.2 years (Standard 
deviation, SD, 14.3). 343,169 (64.3%) claimed at least one prescription for NSAID during a 
follow-up of a mean of 3.9 (SD, 1.6) years (2.2 [SD 1.5] in patients who experienced the 
composite outcome and 4.0 [SD 1.5] in those without). Patients taking non-selective NSAIDs 
were younger and more often men compared with patients taking the selective COX-2 
inhibitors rofecoxib and celecoxib. Patients not taking NSAID had overall more 
comorbidities compared to those taking them. A detailed description of baseline 
characteristics of the study cohort is shown in Table 1. During the study period, 38,226 
(7.2%) individuals experienced the composite outcome. Among 5266 patients, this occurred 
during NSAID treatment. The average daily dosage and average duration treatment were 25.4 
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mg and 31.6 days for rofecoxib, 239.2 mg and 38.9 days for celecoxib, 814.8 mg and 38.8 
days for naproxen, 1295.4 mg and 32 days for ibuprofen and 100.3 mg and 37.1 days for 
diclofenac. We also computed daily dosages for chronic users (>90 days) since the accuracy 
of our estimates becomes better with continued use: the estimates were similar 
(Supplementary table 3). Moreover, we calculated the average daily dosage and average 
treatment duration in patients receiving low and high dosage, respectively: we observed that 
the doses were comparable - for all the drugs they fell just under the threshold that we chose 
for definition of the category; notably, naproxen at low dosage was prescribed for a longer 
period compared to the other NSAIDs (Supplementary table 3).  
 
NSAID use over time 
Regarding the use of NSAID during the study period (Fig. 1), ibuprofen has long been the 
most prescribed NSAID in Denmark with a progressive increase since 2004-2005. The 
prescription of naproxen in Denmark has remained stable and low during the last 20 years. 
The overall use of NSAIDs in patients with OA has remained stable at around 30% in recent 
years. 
 
Main analyses 
In the adjusted model, the overall NSAID use was associated with increased hazard ratio 
(HR) 1.31 (95% confidence interval [CI] 1.27–1.35), compared to no NSAID treatment (Fig. 
2). When studied individually, all the examined NSAIDs were associated with elevated risk 
of the composite outcome compared to no NSAID use. Similar results were seen when fatal 
and non-fatal ischaemic stroke and MI and cardiovascular death were analysed separately 
(Fig. 2).  
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In the dose-related analyses, a dose-dependent increase in risk was seen for the composite 
outcome with the individual NSAIDs (Fig. 3). Low dose of the non-selective NSAIDs, 
naproxen and ibuprofen were associated with the lowest risks regarding the composite 
outcome (HRs 1.12 [1.07-1.19] and 1.16 [0.92, 1.42], respectively), compared to no NSAID 
treatment (Fig. 3). When MI and stroke were examined separately (Supplementary figure 1A 
and 1B), we obtained comparable results. Low dosages of naproxen and ibuprofen were not 
significantly associated with increased risk of cardiovascular death (Supplementary figure 
1C) compared to no NSAID treatment. 
 
Additional analyses 
Ibuprofen as reference 
When compared to ibuprofen (Fig. 4), only naproxen showed a similar cardiovascular risk 
profile: rofecoxib, celecoxib (not for stroke) and diclofenac were associated with greater 
cardiovascular risk. When low-dose ibuprofen (≤1200mg) was used as comparator 
(Supplementary figure 2), rofecoxib, celecoxib and diclofenac had greater HRs for the 
composite outcome at low and high dosages; conversely, naproxen at any dose seemed to 
have neutral effects.  
Celecoxib as reference 
When we performed analyses using celecoxib as reference (Fig. 5), exposure to naproxen and 
ibuprofen was associated with a significantly lower risk of all cardiovascular outcomes 
except for stroke. Similarly, we observed increased HRs for the composite outcome for users 
of low-dose celecoxib (<200 mg) as compared with low-dose ibuprofen and naproxen 
(Supplementary figure 3). 
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Subanalyses 
Repeating the analyses for the composite outcome stratifying for the localization of OA 
(knee, hip or spine) did not affect the results (Supplementary figure 4) as well as when we 
examined separately patients with and without previous cardiovascular disease, respectively 
(Supplementary figure 5 and 6). We found new users of NSAIDs to be associated with a 
significantly higher cardiovascular risk of the composite outcome compared to main analysis 
including both new and prevalent users (Supplementary figure 7). Nevertheless, also among 
new users, celecoxib had an enhanced cardiovascular hazard compared to ibuprofen and 
naproxen (Supplementary figure 7B and 7C).    
The results of the Schneeweiss analysis indicated that the presence of an unmeasured 
confounder, or a combination of confounders, unbalanced distributed in the two compared 
groups by a 17% factor (the overall incidence of obesity in Denmark 
34
), had to increase the 
risk: 1) by a factor of 3.0 to 3.5 in the comparison between NSAID users vs non-NSAID 
users and 2) by a factor of 2.0 to 2.5 in the comparison between celecoxib users and 
ibuprofen users to explain the increased risk observed (Supplementary figure 8 and 9). 
 
Patients who underwent join replacement surgery 
During the follow-up period, 105,606 patients (19.8%) underwent joint replacement surgery, 
80 483 of whom were in the NSAID group. When we evaluated HRs for the composite 
outcome in the perioperative period, exposure to any NSAIDs was related to an elevated risk 
in the adjusted models compared with no treatment: HR 1.11 [1.04-1.18]. Examining the 
different NSAIDs individually, the composite outcome increased significantly by rofecoxib 
1.44 [1.13–1.83] and diclofenac 1.20 [1.04–1.38] and non-significantly by celecoxib and 
naproxen, but not by ibuprofen 1.00 [0.91–1.10] (Supplementary figure 10). 
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Discussion  
In this nationwide study of patients with OA, we found significant differences in the 
cardiovascular profile of individual NSAIDs. All the currently available widely prescribed 
NSAIDs (ibuprofen, naproxen, diclofenac and celecoxib) were associated with elevated 
cardiovascular risk. Low-dose naproxen and ibuprofen seemed to be associated with the 
lowest cardiovascular risk. Compared with these two non-selective NSAIDs, celecoxib 
showed increased cardiovascular risk, even at a low dose. Our results differ from those of two 
recent RCTs, PRECISION and SCOT, which found celecoxib to be non-inferior to ibuprofen 
or naproxen regarding cardiovascular safety. 
14, 35
 
 
Pharmacokinetic and pharmacodynamic characteristics 
Despite their shared analgesic and anti-inflammatory effects and common mechanisms of 
action, NSAIDs differ in pharmacokinetic and pharmacodynamic properties; therefore, small 
but clinically important differences exist in their cardiovascular profile. 
36
 Celecoxib is a 
selective COX-2 inhibitor, with less potency but longer half-life compared to diclofenac. 
12 
Ibuprofen and naproxen inhibit both COX-isoforms: while ibuprofen has a short half-life 
(about 2-3 hr) and hence yields only a transient and reversible block of the COX-1-mediated 
production of thromboxane A2, naproxen has a particularly long half-life which permits a 
sustained suppression of platelet COX-1 activity
 
potentially mimicking the effects of aspirin 
if dosed on a sustained basis. 
12, 37
 However, the potential cardioprotective effect of naproxen 
is difficult to attain outside of a strictly regulated randomized trial and, moreover, its 
pharmacokinetics is characterized by strong interindividual heterogeneity.  
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Results in the context of PRECISION 
Several characteristics may explain the divergent results between PRECISION and our study.  
Firstly, different dosages of the three NSAIDs were compared: in PRECISION, the mean 
daily dose of celecoxib fell into the low dosage group, while in the medium-high for 
ibuprofen and naproxen.
14, 25
 The imbalance was particularly noticeable in patients with OA, 
since ibuprofen and naproxen dose could be increased to provide sufficient pain relief, while 
the daily dosage of celecoxib was capped at 200 mg per day due to regulatory restrictions on 
a per-country basis. 
12, 15
 The effects of NSAIDs, both on pain relief and on the 
cardiovascular system, are closely dose-dependent. 
12
 In PRECISION, the pain control was 
worse in the celecoxib-group compared with the other two drugs: higher rates of drug 
discontinuation due to “insufficient clinical response” and less anti-arthritic efficacy.
14
 
Accordingly, ibuprofen and naproxen were more frequently associated with  renal events and 
hospitalization for hypertension.
14
 Since the thrombogenic effect of NSAIDs is related to the 
degree of COX-2 inhibition, which increases with dose, it is not surprising that PRECISION 
found celecoxib non-inferior in terms of adverse cardiovascular events compared to the two 
non-selective NSAIDs. Analysing equipotent doses, we observed that celecoxib, even at low 
dosages (≤ 200mg), had significantly increased hazard for the composite outcome compared 
to low doses of naproxen (≤ 500mg) and ibuprofen (≤ 1200mg). Our calculation of the 
ingested daily dose relied on an algorithm based on pre-defined typical dosages and prior 
prescription patterns; and it assumed that all reimbursed NSAIDs were taken regularly and at 
a fixed mean daily dosage between prescriptions, which does not always happen in reality. 
We found an average overall daily dosage which fell in the medium dose category for all 
three drugs. 
25
 Concurrently, celecoxib and naproxen had an average duration treatment of 
about 38 days and ibuprofen of 32 days. Also, we observed that the largest part of patients 
took these medications only for short periods of 1-2 weeks, while the mean duration of 
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treatment in PRECISION in all arms was around 20 months. Therefore, we believe that our 
calculations reflect more precisely the clinical practice, where NSAIDs are taken 
intermittently, for short periods, at low or varying dose, and where switch between the 
various drugs often occur. 
13, 38-40
 
Secondly, we studied a Danish cohort of patients with OA, while PRECISION was conducted 
primarily in the USA (>80% subjects) plus 13 different non-European countries. Thirdly, our 
composite outcome included non-fatal MI, stroke and cardiovascular death and hence was 
narrower compared to the Antiplatelet Trialists Collaboration (APTC) outcome. Fourthly, the 
two studies had deeply different designs and related limitations. In our registries, we do not 
have information about important clinical features (blood pressure, smoking habits, left 
ventricular ejection fraction); therefore, the effect of unmeasured confounders cannot be 
completely ruled out. To account for selection differences among diverse NSAIDs, we 
performed subanalyses including only patients with previous cardiovascular diseases, which 
confirmed the main results. Moreover, our Schneeweiss analyses demonstrated that an 
unmeasured confounder must be particularly strong to fully explain our results and the 
existence of such a confounder, when possible, is highly unlikely. However, selective COX-2 
drugs, because of their relative gastrointestinal safety, in clinical practice tend to be 
channelled towards patients with diverse comorbidities, 
41
 as testified by the imbalance in 
cardiovascular diseases between patients taking COX-2 selective drugs and non-selective 
NSAIDs at baseline. Therefore, despite the robustness of our results, the adjustments for 
comorbidities and the several subanalyses, selection bias and residual confounding may have 
influenced our findings. 
The average relative risk of cardiovascular complications associated with NSAIDs is in the 
order of 1.0-2.0. Particularly, a large meta-analysis and a systematic review of observational 
studies found an increased risk of major vascular events for celecoxib at any dose of 1.36 
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(95% CI 1.00-1.84) and at low dose (≤200 mg/d) of 1.16 (95% CI 1.09-1.47) compared to 
non-NSAID use, respectively.
26, 42
 Therefore, although PRECISION included 24,000 arthritis 
patients, it could not be powered enough to detect slight disparities in the cardiovascular 
profile of the three examined NSAIDs. 
15, 16
 Furthermore, despite the analysis by aspirin 
status showed no difference in PRECISION, 
43
 the authors did not update the use of this 
medication during the study course, only available as a baseline characteristic. The use of 
aspirin may have changed considerably during the study period because of its long duration 
(10 years). Notably ibuprofen and naproxen, but not celecoxib, can undermine the 
cardioprotective effects of aspirin. Moreover, patients most dependent on the platelet-
inactivating effect of aspirin, i.e. those with a recent cardiovascular event (<3 months) were 
excluded. Conversely, we updated continually our analyses according to exposure to aspirin: 
this could have contributed to the different results. Finally, distinct inclusion criteria may 
have played an important role on the outcomes and on the findings: for example, patients 
with severe heart failure or patients taking warfarin were excluded from PRECISION. 
44
 
Similarly, patients in PRECISION had a mean duration since first diagnosis of OA of about 
10 years, while we enrolled individuals with first contact with the Danish health care system 
for OA. 
44
  
 
Other studies comparing NSAIDs in patients with OA 
Another recent clinical trial, Standard care vs. Celecoxib Outcome Trial (SCOT), conducted 
in Europe, 
35
 compared celecoxib with non-selective NSAIDs and did not find differences in 
cardiovascular risk between the two groups. However, in this study, all the non-selective 
NSAIDs were grouped together, including diclofenac, which is characterized by a degree of 
COX-2 selectivity and a cardiovascular-hazard comparable with COX-2 inhibitors 
45
 and 
hence may have diluted the result toward non-inferiority of celecoxib. Notably, in our 
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analyses, diclofenac exhibited a magnitude of risk in accordance with previous studies 
5, 46
 
and a cardiovascular risk profile similar to celecoxib. Moreover, patients taking celecoxib had 
a higher drop-out rate than those in the non-selective NSAID group, often for a lack of 
efficacy in pain management. 
17
 Finally, the on-treatment analysis failed to prove non-
inferiority of celecoxib. 
12
   
The results of our study are strengthened by their concordance with the mechanism by which 
NSAIDs are supposed to confer cardiovascular hazard 
12, 47, 48
 and with the conclusions of 
previous large meta-analyses. 
26, 46
  
 
Limitations 
With the observational nature of our study, any conclusion must be drawn with caution.  
The initial symptoms of ischaemic heart disease could be interpreted as musculoskeletal 
disorder and thereafter progress to myocardial infarction. Although NSAIDs are not 
recommended for the treatment of coronary heart disease, we cannot completely exclude the 
possibility that this will happen. Consequently, it is possible that our results overestimate the 
NSAID-associated risk. However, the association of NSAIDs with cardiovascular hazard is 
widely reported 
2, 26, 46, 49
. We studied an OA cohort, which minimized the risk of 
confounding-by-indication. Moreover, at baseline, the subjects not taking NSAIDs had an 
overall higher cardiovascular risk (older age and more comorbidities). It is therefore unlikely 
that confounding-by-indication alone would drive our results. 
In Denmark, from October 2001, ibuprofen, as the only NSAIDs, was available as over-the-
counter medicine, but at low dosage (200mg) and small amounts (maximum 100 tablets). 
However, in the light of the reimbursement obtainable with a prescription, patients requiring 
higher doses or long-term treatment, such as patients with OA, would have a financial 
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incentive to obtain prescriptions from their physician. Moreover, restricting the analyses to 
1996-2000 did not alter the association between NSAIDs and cardiovascular risk. 
 
Conclusions 
This nationwide study of an OA cohort suggests that the use of individual NSAIDs was 
associated with different levels of cardiovascular risk. As NSAIDs are often used in OA, 
these differences could have considerable impact on OA patients’ disease burden. NSAIDs 
with stronger COX-1 selective profiles, such as naproxen and ibuprofen, at the lowest 
effective doses, may be preferred for cardiovascular safety. 
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Figure legends 
Title: Percentage use of different NSAID among patients with OA (1996-2015)  
Figure 1: temporal trend of the use of various NSAIDs among patients with OA during the 
study period (1996-2015). NSAID, Non-Steroidal Anti-Inflammatory Drugs; OA, 
osteoarthritis  
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Title: Risk of all outcomes with usage of specific NSAIDs compared with no NSAID 
treatment 
Figure 2: crude incidence rate and unadjusted and adjusted Cox proportional-hazard ratio of 
composite outcome, fatal and non-fatal stroke, fatal and non-fatal myocardial infarction and 
cardiovascular death associated with use of NSAIDs in patients with osteoarthritis. Reference 
group: no treatment with NSAIDs. NSAID, Non-Steroidal Anti-Inflammatory Drugs. *per 
100-person years  
 
Title: Risk of composite outcomes with usage of different NSAID doses compared with 
no NSAID treatment  
Figure 3: crude incidence rate and unadjusted and adjusted Cox proportional-hazard ratio of 
composite outcome associated with use of NSAIDs in patients with osteoarthritis in 
accordance with dose of the drugs. Reference group: no treatment with NSAIDs. NSAID, 
Non-Steroidal Anti-Inflammatory Drugs. *per 100 person years 
 
Title: Risk of all outcomes with usage of specific NSAIDs compared with ibuprofen 
Figure 4: crude incidence rate and unadjusted and adjusted Cox proportional-hazard ratio of 
composite outcome, fatal and non-fatal stroke, fatal and non-fatal myocardial infarction and 
cardiovascular death associated with use of NSAIDs in patients with osteoarthritis. Reference 
group: patients taking ibuprofen. NSAID, Non-Steroidal Anti-Inflammatory Drugs. *per 100 
person years 
 
Title: Risk of all outcomes with usage of specific NSAIDs compared with celecoxib 
Figure 5: crude incidence rate and unadjusted and adjusted Cox proportional-hazard ratio of 
composite outcome, fatal and non-fatal stroke, fatal and non-fatal myocardial infarction and 
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cardiovascular death associated with use of NSAIDs in patients with osteoarthritis. Reference 
group: patients taking celecoxib. NSAID, Non-Steroidal Anti-Inflammatory Drugs. *per 100 
person years 
 
 
Table 1. Baseline Characteristics of the Total Study Population and Individual 
Treatment Group 
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Characteristic Total 
Population 
(%) 
No 
NSAID 
(%) 
Overall 
NSAID 
(%) 
Rofecoxib Celecoxib Diclofenac Ibuprofen Naproxen Other 
NSAIDs 
Total patients 533 502 
(100) 
190 
333 
(35.7) 
343 
169 
(64.3) 
23 011 
(4.3) 
24 459 
(4.6) 
90 918 
(17.0) 
239 901 
(45.0) 
21 606 
(4.0) 
80 189 
(15.0) 
Mean age 
(SD), y 
62.2 (14.3) 63.6 
(14.9) 
61.4 
(13.8) 
66.5 
(13.2) 
65.9 
(13.0) 
60.3 
(13.7) 
60.2 
(13.8) 
60.1 
(14.2) 
63.1 
(13.5) 
Women 301 795 
(56.6) 
104 
961 
(55.2) 
196 
834 
(57.4) 
15 985 
(69.5) 
16 486 
(67.4) 
52 079 
(57.3) 
134 682 
(56.1) 
12 334 
(57.1) 
50 148 
(62.5) 
Men 231 707 
(43.4) 
85 
372 
(44.8) 
146 
335 
(42.6) 
7026 
(30.5) 
7973 
(32.6) 
38 839 
(42.7) 
105 219 
(43.9) 
9272 
(42.9) 
30 050 
(37.5) 
Comorbidity          
Previous MI 9116 (1.7) 4154 
(2.2) 
4962 
(1.5) 
476 (2.1) 452 (1.9) 1301 (1.4) 3147 (1.3) 325 (1.5) 1244 
(1.6) 
IHD* 37 163 
(7.0) 
15 
877 
(8.3) 
21 286 
(6.2) 
1839 
(8.0) 
1934 
(7.9) 
5509 (6.1) 13 808 
(5.8) 
1369 
(6.3) 
5382 
(6.7) 
Previous 
stroke 
16 293 
(3.1) 
7682 
(4.0) 
8611 
(2.5) 
790 (3.4) 768 (3.1) 2080 (2.3) 5421 (2.3) 475 (2.2) 2121 
(2.6) 
PAD 11 439 
(2.2) 
5168 
(2.7) 
6271 
(1.8) 
555 (2.4) 587 (2.4) 1543 (1.7) 4038 (1.7) 396 (1.8) 1550 
(1.9) 
HF 14 225 
(2.7) 
7188 
(3.8) 
7037 
(2.1) 
787 (3.4) 761 (3.1) 1655 (1.8) 4277 (1.8) 399 (1.9) 1809 
(2.3) 
AF 20 535 
(3.9) 
10 
885 
(5.7) 
9650 
(2.8) 
787 (3.4) 870 (3.6) 2269 (2.5) 6086 (2.5) 583 (2.7) 2199 
(2.7) 
Diabetes 33 635 
(6.3) 
13 
006 
(6.8) 
20 629 
(6.0) 
1029 
(4.5) 
1204 
(4.9) 
5132 (5.6) 14 759 
(6.2) 
1403 
(6.5) 
4701 
(5.9) 
Dyslipidemia 82 593 
(15.5) 
33 
894 
(17.8) 
48 699 
(14.2) 
1123 
(4.9) 
1875 
(7.7) 
10 702 
(11.8) 
36 694 
(15.3) 
3118 
(14.4) 
9710 
(12.1) 
Hypertension 61 774 
(11.6) 
21 
771 
(11.4) 
40 003 
(11.7) 
3672 
(16.0) 
3701 
(15.1) 
10 558 
(11.6) 
26 192 
(10.9) 
2505 
(11.6) 
10 480 
(13.1) 
COPD 17 781 
(3.3) 
7426 
(3.9) 
10 355 
(3.0) 
872 (3.8) 916 (3.8) 2589 (2.9) 6865 (2.9) 628 (2.9) 2568 
(3.2) 
Malignancy 28 777 
(5.4) 
12 
071 
(6.3) 
16 706 
(4.9) 
1303 
(5.7) 
1372 
(5.6) 
4178 (4.6) 11 222 
(4.7) 
955 (4.4) 3777 
(4.7) 
GI-bleeding 12 705 
(2.4) 
6011 
(3.2) 
6694 
(2.0) 
630 (2.7) 650 (2.7) 1630 (1.8) 4266 (1.8) 408 (1.9) 1623 
(2.0) 
CKD 7268 (1.4) 3926 
(2.1) 
3342 
(1.0) 
204 (0.9) 215 (0.9) 844 (0.9) 2250 (0.9) 221 (1.0) 720 
(0.9) 
Osteoporose 24 161 
(4.5) 
10 
936 
(5.8) 
13 225 
(3.9) 
1004 
(4.4) 
1177 
(4.8) 
2749 (3.0) 9053 (3.8) 765 (3.5) 2976 
(3.7) 
Rheumatologic 18 093 6139 11 954 1333 1386 2882 (3.2) 7192 (3.0) 761 (3.5) 3669 
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Abbreviations:
 
MI, myocardial infarction;
 
IHD, ischemic heart disease; PAD, peripheral 
artery disease; HF, heart failure;
 
AF, atrial fibrillation; COPD, chronic obstructive pulmonary 
disease; GI-bleeding, gastrointestinal bleeding; CKD, Chronic kidney disease; ASA, 
acetylsalicylic acid; ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin-2 
disease (3.4) (3.2) (3.5) (5.8) (5.7) (4.6) 
Concomitant 
medical 
treatment 
         
β - blockers 65 641 
(12.3) 
27 
080 
(14.2) 
38 561 
(11.2) 
2548 
(11.1) 
2982 
(12.2) 
9674 
(10.6) 
25 900 
(10.8) 
2462 
(11.4) 
9376 
(11.7) 
ACE inhibitors  66 437 
(12.5) 
25 
793 
(13.6) 
40 644 
(11.8) 
2025 
(8.8) 
2429 
(9.9) 
9450 
(10.4) 
29 053 
(12.1) 
2615 
(12.1) 
8917 
(11.1) 
ARB 48 718 
(9.1) 
18 
889 
(9.9) 
29 829 
(8.7) 
1234 
(5.4) 
1758 
(7.2) 
7073 (7.8) 21 521 
(9.0) 
1780 
(8.2) 
6694 
(8.4) 
Weak opioids 128 642 
(24.1) 
41 
829 
(22.0) 
86 813 
(25.3) 
7231 
(31.4) 
7921 
(32.4) 
23 446 
(25.8) 
58 996 
(24.6) 
5454 
(25.2) 
22 264 
(27.8) 
Strong opioids 50 869 
(9.5) 
18 
053 
(9.5) 
32 816 
(9.6) 
1930 
(8.4) 
2470 
(10.1) 
7781 (8.6) 23 094 
(9.6) 
2165 
(10.0) 
7557 
(9.4) 
NSAIDs** 284 337 
(53.3) 
58 
042 
(30.5) 
226 
295 
(65.9) 
15 966 
(69.4) 
17 564 
(71.8) 
63 198 
(69.5) 
157 064 
(65.5) 
15 076 
(69.8) 
58 618 
(73.1) 
ASA *** 131 186 
(24.6) 
46 
904 
(24.6) 
84 282 
(24.6) 
7482 
(32.5) 
7869 
(32.2) 
22 650 
(24.9) 
55 103 
(23.0) 
5582 
(25.8) 
22 322 
(27.8) 
Joint 
replacement 
surgery **** 
105 606 
(19.8) 
25 
123 
(13.2) 
80 483 
(23.5) 
7232 
(31.4) 
8217 
(33.6) 
22 881 
(25.2) 
53 292 
(22.2) 
5045 
(23.4) 
23 638 
(29.5) 
Bone fractures 
**** 
55 952 
(10.5) 
16 
644 
(8.7) 
39 308 
(11.5) 
3781 
(16.4) 
3800 
(15.5) 
11 036 
(12.1) 
26 949 
(11.2) 
2414 
(11.2) 
10 412 
(13.0) 
Type of OA          
OA of knee 243 848 
(45.7) 
77 
492 
(40.7) 
166 
356 
(48.5) 
12 350 
(53.7) 
12 586 
(51.5) 
45 056 
(49.6) 
116 843 
(48.7)  
10 924 
(50.6) 
42 100 
(52.5) 
OA of hip 160 369 
(30.1) 
54 
330 
(28.5) 
106 
039 
(30.9) 
9308 
(40.5) 
10 349 
(42.3) 
28 838 
(31.7) 
68 549 
(28.6) 
6346 
(29.4) 
27 834 
(34.7) 
OA of spine 84 104 
(15.8) 
27 
825 
(14.6) 
56 279 
(16.4) 
4498 
(19.5) 
4377 
(17.9) 
16 089 
(17.7) 
39 558 
(16.5) 
3564 
(16.5) 
13 552 
(16.9) 
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receptor blockers; NSAID, Nonsteroidal anti-inflammatory drugs; OA, osteoarthritis; 
operations performed during follow-up period 
 
* previous MI not included 
** baseline NSAID treatment was defined as availability of tablets within six months before 
the inclusion  
*** including patients who redeemed prescriptions for aspirin during follow-up  
**** during follow-up period 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5  
 
 
  
